After hours:
Chart Events
Performance Outlook
| Previous Close | 0.9633 |
| Open | 0.9585 |
| Bid | 0.9100 x 1000 |
| Ask | 0.9502 x 1200 |
| Day's Range | 0.8000 - 0.9729 |
| 52 Week Range | 0.5100 - 1.4900 |
| Volume | |
| Avg. Volume | 299,701 |
| Market Cap | 87.583M |
| Beta (5Y Monthly) | 2.64 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3700 |
| Earnings Date | Nov 13, 2023 - Nov 17, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.67 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for CGEN
Related Research
- Compugen Ltd.The Argus Mid-Cap Model PortfolioSmall- and mid-cap stocks (SMID) have underperformed large-caps over the past 12 months, but may be in a better position to generate market-beating returns going forward. SMID companies tend to focus on domestic markets, so their businesses could be less disrupted by the fallout from the Russian invasion of Ukraine, high European inflation or other geopolitical developments. As well, the prices of SMID stocks generally are lower than the prices of large-caps. SMID stocks can be risky, but diversified investors look to have exposure to small- and mid-caps based on the long-term performance record. We estimate that 12%-15% of the U.S. stock market's capitalization is comprised of SMID stocks. For our purposes, we use a threshold of $20 billion to define a SMID stock.RatingFair ValueEconomic MoatyesterdayArgus Research
PR NewswireCompugen to Present New Clinical and Pre-Clinical Data in Multiple Presentations at SITC 2023
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, it will present new clinical and pre-clinical data supporting its vision to extend the reach of cancer immunotherapies to new patient populations, in an oral presentation and four poster presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place between 3-5 November 2023, San Diego, CA.
ZacksIs Aspira Women's Health (AWH) Stock Outpacing Its Medical Peers This Year?
Here is how Aspira (AWH) and Compugen (CGEN) have performed compared to their sector so far this year.
PR NewswireCompugen to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will present virtually at the H.C. Wainwright 25th Annual Global Investment Conference. The presentation will be available on demand on the Investor Relations section of Compugen's website at www.cgen.com from Monday, September 11, 2023, 7:00 AM ET for 30 days.
